Microfluidic cell chip method to analyze CD14+monocyte myeloperoxidase expression in acute myelomonocytic leukemia patients
10.3969/j.issn.1000-8179.20140569
- VernacularTitle:微流控芯片分析M4患者CD14+单核细胞中MPO表达
- Author:
Jingjing SONG
;
Xiaoliang LI
;
Jie LAN
;
Chao SUN
;
Peng GE
;
Chengcheng HONG
;
Xuguo SUN
- Publication Type:Journal Article
- Keywords:
s:single-cell analysis;
leukemia;
myeloperoxidase;
microfluidic chip
- From:
Chinese Journal of Clinical Oncology
2014;(12):771-775
- CountryChina
- Language:Chinese
-
Abstract:
Objective:A method that is based on microfluidic cell chip technology was developed for the first time to analyze CD14+monocyte myeloperoxidase (MPO) expression in myelomonocytic leukemia (M4) patients. CD14+monocyte MPO expression in M4 patients was preliminarily discussed. Methods:a. The chip was prepared by using polydimethylsiloxane as the host material and by secondary foam molding. b. A total of 48 clinically diagnosed M4 patients and 52 patients with normal myelogram were included as the test and control groups, respectively. c. A method based on the microfluidic cell chip approach was established to detect CD14+mono-cytes and to determine the positive rate and degree of MPO expression in the cells. d. The microfluidic cell chip technique was used to compare CD14+monocyte MPO expression in M4 patients with that in the control. Results:a. The designed microfluidic single cell analysis chip allowed the entry of granulocytes into the corresponding microfluidic channels. Thus, blood cells were separated. Numer-ous ghost corpuscles surrounded the separated white blood cells (WBCs). WBC morphology did not show obvious changes. b. The posi-tive rate of MPO expression and the activity of CD14+monocytes in the bone marrow of M4 patients were significantly higher than those in the bone marrow of the control (P<0.05). Conclusion:A method based on microfluidic single cell technology was developed for the first time to analyze the MPO expression in CD14+monocytes. CD14+monocyte MPO activity in M4 patients was significantly higher than in the control. CD14+monocyte MPO activity can be used as an auxiliary examination marker for clinical diagnosis.
